HANGZHOU TIGERMED CONSULTI-H

Hangzhou Tigermed Consulti‑H drops 7.6% after its subsidiary Fangda Holdings halts trading – governance, compliance and market sentiment risks highlighted.

Hangzhou Tigermed Consulti‑H faces a temporary halt as subsidiary Fangda pauses trading; analysts weigh compliance, market volatility, and future upside for investors.

Hangzhou Tigermed Consulti‑h’s modest 0.65% rise amid market volatility signals a temporary rebound in the medical‑consultancy sector, offering a cautious investment signal for health‑services traders.